Speciality Medicines IPO

About Speciality Medicines IPO

The Speciality Medicines IPO opens on Friday, March 20, 2026 and closes on Tuesday, March 24, 2026. The allotment of shares will take place on Wednesday, March 25, 2026. The credit of shares to the demat account will take place on Friday, March 27, 2026. The initiation of refunds will take place on Friday, March 27, 2026. The listing of shares will take place on Monday, March 30, 2026.

The offer consists of a fresh issue component. The fresh issue will include 0.24 crore shares of ₹29.14 crores. The total number of shares and aggregate amount are 23,50,000 shares (aggregating up to ₹29 crores).

Speciality Medicines IPO’s price band is set at ₹117 to ₹124 per share. The lot size for an application is 1,000. The minimum amount of investment required by a retail investor is ₹2,48,000 (2,000 shares) (based on upper price). The minimum lot size for investment required by HNIs is 3 lots (3,000 shares), amounting to ₹3,72,000.

Speciality Medicines is engaged in the business of marketing and distribution of finished formulations of specialty pharmaceutical products, consisting of high-cost oral and injectable medications used in the treatment of complex and chronic medical conditions in therapeutic areas like oncology, immunology, neurology and rare diseases. They offer a diverse portfolio of specialty pharmaceutical products, focusing on various therapeutic areas such as oncology, immunology, neurology, and rare diseases.

Objectives of Speciality Medicines IPO

• Setting up of Research and Development (R&D) Centre at Revenue City Survey No. RV1/NA/61/1/50, Moje: Manda, Tal. Umargam, Dist. Valsad, Gujarat.

• Product registration in international markets and product development for sale in international markets.

• Funding for marketing and promotional activities.

• To meet working capital requirements.

• General corporate purpose.

Industry Outlook

The Indian pharmaceutical industry is projected to grow at a Compounded Annual Growth Rate (CAGR) of 9.53%, reaching a market size of INR 7,20,519 crores by 2030. This growth trajectory reflects strong domestic demand, increasing exports, government policy support under initiatives like the Production Linked Incentive (PLI) scheme, and deeper integration of technology and digital healthcare models across the pharmaceutical value chain.

About Speciality Medicines

Speciality Medicines is engaged in the marketing & distribution of finished formulations of specialty pharmaceuticals - high-cost oral or injectable medications used to treat complex chronic conditions in both domestic and international markets. Having cultivated strong and dependable customer relationships in specialty pharmaceuticals, they have, through their distributions, established good rapport with their customers spanning more than 20 states of India and more than 35 countries worldwide. Their mission is to enhance patient care by supplying high-quality, innovative medicines that address unmet medical needs. With a strong commitment to excellence, they aim to make a positive impact on the lives of patients worldwide.

They deal in specialty pharmaceutical finished formulations: capsules, cream, eye drops, gel, infusion, inhalation, inhaler, injection, nasal spray, ointment, ophthalmic preparations, oral solution, oral suspension, sachet, suspension and tablet. They offer a diverse portfolio of specialty pharmaceuticals, focusing on therapeutic areas such as oncology, immunology, neurology, and rare diseases. Their products are designed to meet the complex needs of patients with chronic conditions, providing innovative solutions that improve health outcomes.

Strengths of Speciality Medicines

• Diversified global presence.

• Diversified product portfolio.

• Long standing client relationship.

• Experienced promoters and management team.

• Quality assurance.

Risks of Speciality Medicines

• They rely on third-party suppliers for the supply of their products.

• They derive a significant part of their revenue from major customers.

• They rely on limited suppliers for their products.

• Do not have any experience in Research and Development activities and will be dependent on professional staff to be appointed by the company.

• Their international operations expose them to complex management, legal, tax and economic risks.

Anchor Investor Bidding Date: Friday March 20, 2026

Registrar: Skyline Financial Services Private Limited

Book Running Lead Managers: Unistone Capital Private Limited

Speciality Medicines Business Model

The company earns its revenue through the marketing & distribution of finished formulations of specialty pharmaceuticals - high-cost oral or injectable medications used to treat complex chronic conditions in both domestic and international markets.

Speciality Medicines Growth Trajectory

(Restated Standalone)

Speciality Medicines’ Total Income for FY25 was ₹58.540 crores, whereas in FY24, it was ₹27.657 crores.

The Profit After Tax for FY25 was ₹8.608 crores, whereas in FY24 it was ₹2.934 crores.

Their EBITDA for FY25 was ₹9.092 crores, whereas in FY24 it was ₹5.261 crores.

Speciality Medicines Market Position

They have established their presence in international markets through products that are either registered or in the process of registration in countries, which include Jordan, Ethiopia, Uganda, Peru and Namibia. They have, through their distributions, established good relationships with their customers spreading across more than 20 states of India and more than 35 countries all over the world.

As of March 31, 2025, the company’s Total Income, Profit After Tax, and EBITDA were ₹58.540 crores, ₹8.608 crores, and ₹9.092 crores, respectively.

How to apply for Speciality Medicines IPO?

• Step 1:  Log in to your Kotak Neo Demat account to access IPO investments. Next, select the current IPO section.

• Step 2:  Specify IPO details. Enter the number of lots and the price you wish to apply for.

• Step 3:  Enter UPI ID. After entering your UPI ID, click submit. This will place your bid with the exchange.

• Step 4:  Mandate Notification. Your UPI app will receive a mandate notification to block funds.

• Step 5: Approve Request. Your funds will be blocked once you approve the mandate request on your UPI.